1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 51,75 | 52,05 | 29.08. | |
| 51,75 | 51,95 | 28.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Gubra A/S: Gubra announces achievement of milestone from AbbVie following initiation of a Phase 2 clinical trial of ABBV-295, a long-acting amylin analog | 196 | GlobeNewswire (Europe) | ABBV-295 is a long-acting amylin analog that represents a mechanistically distinct class from incretin-based therapies such as GLP-1 and GIP receptor agonists. Under Gubra's license agreement with AbbVie... ► Artikel lesen | |
| 20.08. | Gubra H1 2026 slides: pipeline advances as CRO returns to profit | 30 | Investing.com | ||
| 20.08. | Gubra A/S: Interim report H1 2026: Strong clinical pipeline momentum and business execution position Gubra for an exciting period ahead | 395 | GlobeNewswire (Europe) | GUB-UCN2, Gubra's next potential mega program, advanced into clinical development with initiation of a comprehensive Phase 1/2a trial.Partnered obesity programs advancing into Phase 2, with Boehringer... ► Artikel lesen | |
| 28.07. | Gubra A/S: Gubra announces initiation of ambitious Phase 1/2a clinical trial of lead asset GUB-UCN2 in obesity | 522 | GlobeNewswire (Europe) | Gubra today announced the initiation of the first-in-human trial of GUB-UCN2, the company's next mega program, with the first participant completing the first visit. The ambitious Phase 1/2a clinical... ► Artikel lesen | |
| 16.07. | Gubra A/S: Boehringer Ingelheim initiates Phase 2 clinical trial of Gubra-originated triple receptor agonist for people living with overweight and obesity | 519 | GlobeNewswire (Europe) | Gubra today announces that its partner Boehringer Ingelheim has initiated a Phase 2 clinical trial of BI 3034701, an investigational, potential first-in-class GLP-1/GIP/NPY2 triple receptor agonist... ► Artikel lesen | |
| 10.07. | Gubra A/S: Gubra collaboration partner Hemab to present preclinical results for HMB-003, a potential treatment for multiple bleeding disorders, at the ISTH 2026 Congress | 394 | GlobeNewswire (Europe) | Copenhagen, July 10, 2026: Gubra's collaboration partner Hemab will present preclinical results from the HMB-003 program on July 11, 2026, at the ISTH Congress in Paris.
The preclinical data show that... ► Artikel lesen | |
| 06.05. | Gubra Q1 2026 slides: obesity pipeline advances amid CRO headwinds | 24 | Investing.com | ||
| GUBRA Aktie jetzt für 0€ handeln | |||||
| 06.05. | Gubra Q1 2026: Fortschritte in der Adipositas-Pipeline bei Gegenwind im CRO-Geschäft | 56 | Investing.com Deutsch | ||
| 06.05. | Gubra A/S: Trading statement Q1 2026: Continued advancement of Biotech portfolio | 659 | GlobeNewswire (Europe) | Today, Gubra releases its results for the first quarter of 2026, building on a record year in 2025. In the quarter, we advanced our Biotech business, not least shown by strong results and progress for... ► Artikel lesen | |
| 28.04. | Gubra A/S: Boehringer Ingelheim advances Gubra originated obesity triple agonist peptide into Phase 2 development | 959 | GlobeNewswire (Europe) | Gubra today notes that its partner Boehringer Ingelheim plans to initiate Phase 2 clinical development in mid-2026 of BI 3034701, an investigational, potential first-in-class triple GLP-1, GIP and NPY2... ► Artikel lesen | |
| 09.03. | Gubra A/S: AbbVie reports Positive Phase 1 Multiple Ascending Dose Results for ABBV-295, a Long-Acting Amylin Analog | 875 | GlobeNewswire (Europe) | Gubra's partner AbbVie today announced positive topline results from the 12 and 13-weeks Phase 1 Multiple Ascending Dose (MAD) trial showing that ABBV-295 was well tolerated with a dose-dependent significant... ► Artikel lesen | |
| 27.02. | Gubra A/S: Annual Report 2025: A record year | 918 | GlobeNewswire (Europe) | Today, Gubra releases its Annual Report for 2025 showing the strongest financial results in Gubra's history. Group revenue and operating profit amounted to DKK 2.6 billion and DKK 2.2 billion, respectively.... ► Artikel lesen | |
| 26.02. | Gubra A/S: Gubra submits clinical trial application for First-in-Human study of lead asset GUB-UCN2 | 937 | GlobeNewswire (Europe) | Gubra today announces that a clinical trial application (CTA) for the first-in-human study of GUB-UCN2, the company's lead asset for high quality weight loss, has been submitted to the Competent Authority... ► Artikel lesen | |
| 10.02. | Gubra A/S: Gubra launches Gubra Ventures and appoints Zoë Johnson to lead new venture creation unit | 466 | GlobeNewswire (Europe) | Gubra today announced the launch of Gubra Ventures, a new business unit focused on creating independent biotechnology companies from high-quality scientific innovation. Zoë Johnson has been appointed... ► Artikel lesen | |
| 08.01. | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | 532 | GlobeNewswire (Europe) | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| 05.01. | Gubra A/S: Gubra appoints Dr. Thomas Langenickel as Chief Medical and Development Officer | 603 | GlobeNewswire (Europe) | Gubra today announced the appointment of Thomas Langenickel, M.D., as Chief Medical and Development Officer (CMDO). Dr. Langenickel brings more than two decades of experience in big pharma and biotech... ► Artikel lesen | |
| 02.01. | Gubra A/S: Gubra Announces Expansion of Facilities to Support Continued Growth Across Its Businesses | 1.247 | GlobeNewswire (Europe) | Gubra A/S ("Gubra") today announced a significant expansion of its laboratory and office facilities at DTU Science Park, located in immediate proximity to the company's headquarters in Hørsholm, Denmark.... ► Artikel lesen | |
| 16.12.25 | Gubra A/S: Gubra and Camurus Enter into a Collaboration and License Agreement to Develop a Long-acting Treatment for Hypoparathyroidism | 466 | GlobeNewswire (Europe) | Gubra A/S ("Gubra"), a company specialized in peptide-based drug discovery, and Camurus AB ("Camurus"), an international, science-led biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| 08.12.25 | Gubra A/S: Boehringer Ingelheim advances next generation triple-agonist peptide for the treatment of obesity into mid-stage development | 764 | GlobeNewswire (Europe) | · Favorable Phase I profile and encouraging weight loss signals of potential first-in-class triple agonist BI 3034701 supports further development
Gubra partner Boehringer Ingelheim today announced... ► Artikel lesen | |
| 10.11.25 | Reporting of Transactions Made by Persons Discharging Managerial Responsibilities and Persons Closely Associated with them in Gubra A/S' Shares | 530 | ACCESS Newswire | HØRSHOLM, DK / ACCESS Newswire / November 10, 2025 / Gubra (CPH:GUBRA)Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company") hereby notifies receipt of information... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,30 | +0,11 % | Kurssprünge und Kaufempfehlungen! Neues Kursziel bei Almonty! CTS Eventim und BioNTech melden sich zurück! | Was für ein Comeback! Im August ist die Aktie von Almonty um über 50 % explodiert! Dafür gibt es gute Gründe. Wolfram ist im Westen knapp und wird von der hochfahrenden Waffenproduktion in den USA dringend... ► Artikel lesen | |
| EVOTEC | 3,348 | -1,06 % | Rheinmetall-Aktie verkaufen? Evotec mit KI-Fantasie? Lahontan Gold hebt Ressourcenschätzung um 22 %! | Soll man die Rheinmetall-Aktie verkaufen? Dazu rät jedenfalls mwb Research. Die Analysten sehen Rheinmetall operativ weiterhin als klaren Gewinner des europäischen Rüstungsbooms. Doch die Erwartungen... ► Artikel lesen | |
| BB BIOTECH | 59,40 | -0,17 % | Edison Investment Research Limited: Edison issues report on BB Biotech (BION) | Edison Investment Research Limited
Edison issues report on BB Biotech (BION) 28-Jul-2026 / 14:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
| MEDIGENE | 0,006 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| QIAGEN | 37,590 | -0,42 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN ernennt Jonathan M. Pratt zum Vorstandsvorsitzenden | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Personalentscheidungen / Vorstand/Strategische Unternehmensentscheidung
QIAGEN N.V.: QIAGEN ernennt Jonathan M. Pratt zum Vorstandsvorsitzenden... ► Artikel lesen | |
| MODERNA | 119,06 | -0,03 % | Merck, Vidac Pharma, Moderna - Neue Krebswaffen elektrisieren die Börse | Ein Durchbruch in der Krebsforschung versetzte die Börse in der vergangenen Woche in Euphorie. Eine personalisierte mRNA-Therapie hat erstmals in einer großen Phase-3-Studie entscheidende Ziele erreicht... ► Artikel lesen | |
| VALNEVA | 2,798 | +0,76 % | Valneva: Impfstoff-Pionier mit starkem Fokus auf langfristige Innovation | ||
| AMGEN | 371,90 | -0,35 % | Amgen: Tezspire Demonstrates Positive Phase 3 Results In Eosinophilic Esophagitis Across Both Co-primary And All Key Secondary Endpoints | Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52
Efficacy in a Third Epithelial-Driven... ► Artikel lesen | |
| EPIGENOMICS | 0,900 | -1,10 % | PTA-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2026 | DJ PTA-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2026
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR Schlagwort(e): Geschäftszahlen / Halbjahr
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 7,950 | -0,62 % | Novavax announces regulatory approvals for updated COVID shot | ||
| STRYKER | 285,30 | -0,07 % | Do Options Traders Know Something About Stryker Stock We Don't? | ||
| BIOGEN | 187,62 | -0,51 % | Veeva Systems: Veeva Vault CRM Selected by Biogen | Unified commercial platform to help speed the delivery of medicines to patientsPLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Biogen has... ► Artikel lesen | |
| BIOFRONTERA | 2,500 | +2,46 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale
Veröffentlichung von Insiderinformationen gemäß... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,610 | +1,16 % | EQS-News: Heidelberg Pharma AG und Huadong Medicine erhalten NMPA-Genehmigung für klinische Studie mit HDP-101 als Kombinationstherapie in China | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Studie
Heidelberg Pharma AG und Huadong Medicine erhalten NMPA-Genehmigung für klinische Studie mit HDP-101 als Kombinationstherapie... ► Artikel lesen | |
| ILLUMINA | 186,64 | +0,27 % | $100 Invested In Illumina 20 Years Ago Would Be Worth This Much Today |
Das Unternehmen GUBRA A/S kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,25 % bei einem Aktienkurs von 52,50 Euro. Die Dividendendrendite beträgt aktuell 0,00 % (berechnet anhand der Ausschüttung von 0,00 Euro in den letzten 12 Monaten).
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GUBRA A/S finden Sie auf Wallstreet Online.